Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

NCT06548607 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

SLE (Systemic Lupus)
Systemic Sclerosis
ANCA Associated Vasculitis
Idiopathic Inflammatory Myopathies
Sjogren's Syndrome
Autoimmune Diseases

Interventions

DRUG: CD19 or CD19-BCMA CAR-T

Sponsor

Nanjing Bioheng Biotech Co., Ltd.